Oligonucleotide Deals Up 2400% in 2026 — Here's the Data

Twenty-five oligonucleotide deals closed between January 13 and July 13, 2026 — up from exactly one in the prior six-month window. That's a 2400% increase, period over period, and it represents the single largest modality-specific deal surge Ambrosia has tracked this year. The driver isn't mysterious: Big Pharma is racing to fill RNA-targeted pipeline gaps before the next wave of clinical readouts shifts leverage even further toward licensors.

The Data — Oligonucleotide Deal Activity, Period over Period

A single deal in H2 2025 was an anomaly, not a baseline. But even adjusting for cyclicality and a slow back half of 2025 across all modalities, 25 deals in six months is unprecedented for oligonucleotides. For context, the entire oligonucleotide licensing category averaged roughly 30–40 deals per full year in 2023 and 2024. We're already at 25 with five and a half months of runway left in 2026. This isn't a blip — it's a structural reallocation of BD capital toward nucleic acid therapeutics.

What's Driving the Trend

Pipeline gaps at scale. At least six of the top-20 pharma companies by revenue entered 2026 with zero or one oligonucleotide program in Phase II or later. Alnylam's continued commercial execution with Onpattro and Amvuttra — plus Ionis's expanding label for eplontersen — proved the commercial model works. The remaining holdouts aren't skeptical about the science anymore; they're skeptical they can build internally fast enough. That urgency is showing up in deal terms: upfronts are climbing, and option structures are giving way to outright exclusive licenses.

Delivery platform maturation. GalNAc-conjugate delivery for liver targets is now table stakes. The real dealmaking heat is around extrahepatic delivery — muscle, CNS, lung. Arrowhead's TRiM platform and Ascidian's RNA editing approach both address tissue targets beyond the liver, which explains why Sarepta and Lilly paid up. Every pharma company with a neurology or cardiometabolic franchise is now hunting for a delivery platform partner, and supply of credible ones is thin.

Regulatory tailwinds. The FDA approved five oligonucleotide-based therapies between 2023 and mid-2026, with no CRLs in the modality during that window. That's an unusually clean regulatory track record compared to cell therapy or gene therapy, where manufacturing holds and clinical holds have introduced caution. Regulatory confidence de-risks the modality at the portfolio level, which is exactly how large pharma BD committees think about capital allocation. You can benchmark how these regulatory signals affect deal valuations using our Deal Benchmarks tool.

Notable Deals

Arrowhead–Sarepta ($500M upfront / $10B TDV) is the deal that resets the market. Sarepta, already dominant in Duchenne with its gene therapy franchise, is making a deliberate bet that RNA-targeted approaches will be the next standard of care in neuromuscular disease. The $500M upfront is the largest cash commitment to an oligonucleotide licensor since Alnylam's Roche deal in 2021. A $10B total deal value signals that Sarepta is pricing in blockbuster-level commercial expectations — which, given their existing Duchenne infrastructure, isn't unreasonable. This deal will be cited in every oligonucleotide term sheet negotiation for the next 18 months.

Argo Biopharma–Novartis ($160M upfront) is notable because Argo is a relatively young company. Novartis paying $160M upfront for a platform-stage asset from a sub-5-year-old biotech tells you the premium is on the delivery technology, not just the lead program. Novartis has been methodically building an oligonucleotide portfolio since its 2024 restructuring, and this deal fills a specific extrahepatic gap.

Ascidian–Eli Lilly ($1.9B TDV) deserves attention because Ascidian's RNA editing platform represents a next-generation approach — not traditional antisense or siRNA, but programmable ADAR-mediated editing. Lilly is paying for optionality across multiple therapeutic areas. The undisclosed upfront is notable in itself; when upfronts aren't disclosed at this TDV level, it often means the structure is heavily milestone-weighted, which suggests Lilly is managing downside risk while locking in access.

Silence–Hansoh ($16M upfront) sits at the other end of the spectrum and is a useful corrective. Not every oligonucleotide deal is a mega-deal. Hansoh's $16M upfront for Greater China rights reflects the reality that regional licensing deals still trade at steep discounts to global rights — and that GalNAc-siRNA liver programs, while proven, no longer command premium economics unless paired with differentiated targets.

What This Means for BD Teams Right Now

If you're a licensor: This is the strongest seller's market in oligonucleotide history. Upfront-to-TDV ratios are compressing, meaning buyers are putting more cash upfront relative to total deal value. The Arrowhead deal's 5% upfront-to-TDV ratio is actually conservative by current standards — several undisclosed deals in the dataset show upfront ratios closer to 8–10%. If you have a credible extrahepatic delivery platform, you should be running a competitive process with at least three potential licensees. Accepting a bilateral term sheet in this market is leaving money on the table. Use the Ambrosia Deal Calculator to model what your asset should command at current multiples.

If you're a licensee: Speed matters more than precision right now. The supply of differentiated oligonucleotide platforms — particularly those with extrahepatic proof of concept — is genuinely limited. We count fewer than 15 independent companies globally with clinical-stage extrahepatic delivery data. At the current pace of dealmaking, half of those will be partnered by Q4 2026. Waiting for Phase II data to de-risk your diligence is a rational instinct, but by the time that data reads out, someone else will have signed the term sheet. The winning strategy is structured optionality: take a platform license with program-specific opt-ins, and front-load the upfront to outbid slower-moving competitors.

Deal structures to watch: Co-development and co-commercialization structures are gaining traction in this space, particularly for U.S. rights. We're seeing at least three deals in the current window where the licensor retained co-promote rights — a structure that was rare in oligonucleotide licensing even 12 months ago. This reflects licensor confidence that the modality is commercially viable and that retaining economics is worth the operational complexity. If you're negotiating against a co-promote ask, expect to pay a 20–30% premium on upfront to buy the licensor out of those rights.

Benchmark Your Deal

The oligonucleotide deal trends in 2026 have fundamentally reset valuation anchors for the modality. If you're negotiating an oligonucleotide license — buy-side or sell-side — you need current comps, not 2024 precedents. Benchmark your deal against current market rates with the Ambrosia calculator. The data updates in real time as new deals are captured, so your term sheet reflects what the market is actually paying, not what it paid 18 months ago.